Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Payables: 2022-2024

Historic Payables for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $13.6 million.

  • NewAmsterdam Pharma Co N.V's Payables fell 4.56% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.2 million, marking a year-over-year decrease of 13.59%. This contributed to the annual value of $13.6 million for FY2024, which is 19.59% down from last year.
  • As of FY2024, NewAmsterdam Pharma Co N.V's Payables stood at $13.6 million, which was down 19.59% from $16.9 million recorded in FY2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Payables peaked at $16.9 million during FY2023, and registered a low of $11.9 million during FY2022.
  • In the last 3 years, NewAmsterdam Pharma Co N.V's Payables had a median value of $13.6 million in 2024 and averaged $14.1 million.
  • Its Payables has fluctuated over the past 5 years, first surged by 42.77% in 2023, then decreased by 19.59% in 2024.
  • NewAmsterdam Pharma Co N.V's Payables (Yearly) stood at $11.9 million in 2022, then surged by 42.77% to $16.9 million in 2023, then dropped by 19.59% to $13.6 million in 2024.